Get started

PFIZER

Up..Up..& Away! Priority Review for Cancer DrugAt 8:30 AM NEWS This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer. The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much. Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news. At 4:05 PM NEWS Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis. This company has a lot of positive things moving forward including... On 6/11/2020, the stock got a boost with a price target of $45.00 a share. Daily Chart looks good with indicators turning up, Bullish Weekly Chart also looks Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
PFIZER SHORT Trading PlanEU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe. Hence, I expect the share price will dip further. Key Trading Plan: i) SHORT when it reaches the pull back price at 34.98 and it breaks support level at 32.87 before reaching target Take Profit point at 28.28. ii) LONG when the price breaks the resistance level of 36.89 with the target Take Profit point at 39.33 Author: S.I.D. Aizu
NYSE:PFEShort
by SIDCapital
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors. Why? Because the 'bottom' has been gauged by this piece of over the weekend news. The bad news does not materially affect existing revenue stream and earnings. The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open. Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50. Perfect opportunity for a long trade, short term or long. Anything above 34.50 is a BUY. Interval Targets are the Fibonacci levels on the chart. Final target: $45
NYSE:PFELong
by yujingr
Pfizer Shizer; Do the Bears Have this One? 🏥 | PFIZER ($PFE)🧑‍⚕️ Pfizer recently announced that a clinical trial of its drug Ibrance hasn't worked out as a long-term treatment for breast cancer. This news is unfortunate on a few levels, but specifically, in terms of price, the impact isn't great. Upon releasing the news PFE dumped as analyst began to revise earnings expectations downward. This sell-off caused a reversal of the shorter term post-COVID downtrend and caused what appears to be a return to the pre-COVID downtrend. While we do think a short setup makes sense here given the facts, there is plenty of reason to be bullish from a longer-term point of view given Pfizer's projection that it could have a COVID vaccine by fall and given their funding of other COVID companies working on treatments. Resources: www.jpost.com + www.marketwatch.com + www.barrons.com ✨ Drop a comment asking for an update, we do NEW setups every day! ✨ Like, Comment & Follow to help the community grow 🎉🎉 --- 1. Fractal Trend is showing a fresh downtrend (Maroon colored bars) on the 1-hour timeframe. 2. With this strategy, we are looking for short setups in an downtrend and as such want to enter short on retests of bearish order blocks plotted by Orderblock Mapping (Maroon colored lines) and/or bearish S/R levels plotted by Directional Bias (Maroon colored lines). 3. The play here is simple, we are looking for a reaction at the R1 S/R flip and then are targeting the S1 orderblock at the current low. Then, by placing a stop just above the S/R flip, we have ourselves a solid 4.09 risk/reward ratio. 4. Other levels to the upside to watch here are R2 and R3 bearish orderblocks which should see a reaction if and when we move to the upside. 5. Below, the S2 and S3 bullish orderblocks should provide support if we move to the downside. Keep in mind we are only looking to short weakness in the near term here, as time goes on PFE should find support and potential COVID cures could easily send this stock back up. Until then, good luck bears!
NYSE:PFE
by AlphaBotSystem
1
Pfizer -PFE - Technical and Fundamental AnalysisTechnical Analysis: Wait that the upper resistance line will be broken before buying. The prices are in a sideways trend, theoretically they should resume their previous trend (uptrend) breaking the top resistance dotted line. Fundamental Analysis: Pharmaceutical giant Pfizer (NYSE:PFE), which is working alongside German drugmaker BioNTech (NASDAQ:BNTX) to develop a coronavirus vaccine, says it should have initial data from its stage one clinical trial in mid-to-late June.
NYSE:PFELong
by Mauriello